Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Clinical Pharmacology & Therapeutics, vol. 119, pp. 1156–1159

Abstract

ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or socioeconomic status, should have access to high-quality and evidence-based therapies. This perspective spotlights the network's contributions toward this goal and identifies priority areas to build equitable health outcomes.

Authors 14

1. Priya Jayachandran corresponding

   Regeneron (United States)

   Affiliation as printed

   Regeneron Pharmaceuticals, Inc. Tarrytown New York USA

2. Mayur K. Ladumor

   Merck & Co., Inc., Rahway, NJ, USA (United States)

   Affiliation as printed

   Merck & Co., Inc. West Point Pennsylvania USA

3. Georgios Vlasakakis

   GlaxoSmithKline (United States)

   Affiliation as printed

   GSK Collegeville Pennsylvania USA

4. Andrew M. Riselli

   Gilead Sciences (United States)

   Affiliation as printed

   Clinical Pharmacology Sciences, Gilead Sciences, Inc. Foster City California USA

5. Katarina Ilić
   Affiliation as printed

   Expert Consultant Drug Safety, Clinical Pharmacology, Clinical Development, Pharmacoepidemiology USA

6. Rob Christiaan van Wijk Aachen Division of Systems Pharmacology and Pharmacy Leiden Academic Centre for Drug Research

   Leiden University

   Affiliation as printed

   Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands

7. Mohamed A. Elmeliegy

   Pfizer (United States)

   Affiliation as printed

   Oncology Research and Development, Pfizer Inc. San Diego California USA

8. Jatinder Kaur Mukker

   EMD Serono, Inc. (United States) · Merck Healthcare KGaA, Darmstadt (Germany)

   Affiliation as printed

   Quantitative Pharmacology, EMD Serono Billerica Massachusetts USA

9. Aarti Sawant‐Basak

   AstraZeneca (United States)

   Affiliation as printed

   Clinical Pharmacology and Pharmacometrics, CPSS, AstraZeneca Waltham Massachusetts USA

10. Long Tao

    Takeda (United States)

    Affiliation as printed

    Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA) Cambridge Massachusetts USA

11. Juyao Ivy Dong

    AbbVie (United States)

    Affiliation as printed

    Abbvie, Development Science Irvine California USA

12. Noha Rayad

    AstraZeneca (Canada)

    Affiliation as printed

    Alexion, AstraZeneca Rare Disease, Clinical Pharmacology & Safety Sciences Mississauga Ontario Canada

13. Tao Zhang

    Binghamton University

    Affiliation as printed

    School of Pharmacy and Pharmaceutical Sciences Binghamton University, State University of New York Binghamton New York USA

14. the DRO Network